Profusa (NASDAQ:PFSA) vs. Nanovibronix (NASDAQ:FEED) Critical Survey

Profusa (NASDAQ:PFSAGet Free Report) and Nanovibronix (NASDAQ:FEEDGet Free Report) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

Valuation & Earnings

This table compares Profusa and Nanovibronix”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Profusa N/A N/A -$8.71 million ($2.23) -1.37
Nanovibronix $2.56 million 1.35 -$3.70 million ($41.74) -0.08

Nanovibronix has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

9.8% of Profusa shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 11.4% of Profusa shares are held by insiders. Comparatively, 5.2% of Nanovibronix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Profusa and Nanovibronix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Profusa N/A N/A -880.32%
Nanovibronix -275.12% -24.78% -19.24%

Analyst Recommendations

This is a summary of current ratings and target prices for Profusa and Nanovibronix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Profusa 1 0 0 0 1.00
Nanovibronix 1 0 0 0 1.00

Risk & Volatility

Profusa has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, indicating that its stock price is 121% more volatile than the S&P 500.

Summary

Nanovibronix beats Profusa on 6 of the 10 factors compared between the two stocks.

About Profusa

(Get Free Report)

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.

About Nanovibronix

(Get Free Report)

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.

Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.